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Research
Bisphenol A (BPA) is a synthetic compound 
that is a suspected endocrine disruptor—a 
compound capable of causing dysfunction to 
hormonally regulated body systems (Talsness 
et al. 2009). BPA is used as a monomer in 
polycarbonate plastics and in the epoxy resins 
that are used to line food and beverage con-
tainers; it is one of the world’s highest pro-
duction volume chemicals (Burridge 2003). 
Widespread and continuous daily exposure 
to BPA is believed to occur primarily through 
the diet (Stahlhut et al. 2009), as well as from 
drinking water, dental sealants, dermal expo-
sure, and inhalation of household dusts. The 
presence of measurable concentrations of 
metabolites has been reported in the urine of 
> 90% of people in population-representative 
samples from across the globe (Calafat et al. 
2008; Vandenberg 2007).
Most studies of the health effects of BPA 
have focused on its well-documented estro-
genic activity, with reports of both estro-
gen agonist (Lee et al. 2003) and androgen 
antagonist activity (Bonefeld-Jørgensen et al. 
2007; Lee et al. 2003; Okada et al. 2008). 
Suppression of aromatase activity has been 
observed in laboratory studies (Bonefeld-
Jørgensen et al. 2007), as has binding to alter-
native nuclear receptors, including the aryl 
hydrocarbon receptor (Kruger et al. 2008) and 
estrogen-related receptor γ, the function of 
which remains unknown (Okada et al. 2008). 
In addition, BPA has been reported to cause 
thyroid hormone disruption (Moriyama et al. 
2002), altered pancreatic beta-cell function 
(Ropero et al. 2008), and obesity- promoting 
effects (Newbold et al. 2008). The poten-
tial for low-dose effects has prompted debate 
on revising the current legislation of recom-
mended safe daily exposure levels (Beronius 
et al. 2010; vom Saal et al. 2007).
Based on the animal and laboratory evi-
dence, we previously hypothesized that higher 
urinary BPA concentrations would be associ-
ated with adverse human health effects. Using 
data from the U.S. National Health and 
Nutrition Examination Survey (NHANES) for 
2003–2004, the first large-scale population-
based epidemiological data on urinary BPA 
concentrations with sufficient power to detect 
low-dose effects, we showed for the first time 
a clear correlation between BPA exposure and 
disease in humans (Lang et al. 2008). Higher 
BPA concentrations in NHANES respondents 
were associated with diagnoses of cardiovas-
cular disease and diabetes but not with other 
common diseases, which suggested specificity 
of the reported findings (Melzer et al. 2008, 
2009). We recently used an entirely new study 
sample from the 2005–2006 NHANES to 
conduct an independent replication of the 
association of BPA and cardiovascular disease 
(Melzer et al. 2010). The results of this repli-
cation indicated that chance was an implau-
sible explanation for our results.
Studies to clarify the mechanisms of these 
associations are clearly a priority. A substan-
tive literature documents the disruption of 
circulating reproductive hormone concentra-
tions after BPA exposures in animal mod-
els (reviewed by Richter et al. 2007; see also 
Bonefeld-Jørgensen et al. 2007; Goodman 
et al. 2009; Talsness et al. 2009). Studies of 
human populations have until now been lim-
ited to very small sample sizes. A significant, 
positive relationship was reported between 
circulating androgen concentrations and 
BPA exposure in a small study of 26 normal 
women and 47 women with ovarian dysfunc-
tion (Takeuchi et al. 2004). More recently, 
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Background: Bisphenol A (BPA) is a high production volume chemical widely used in packaging 
for food and beverages. Numerous studies have demonstrated that BPA can alter endocrine function 
in animals, yet human studies remain limited.
oBjective: We estimated daily excretion of BPA among adults and examined hypothesized associa-
tions with serum estrogen and testosterone concentrations.
Methods: We conducted cross-sectional analyses using data from the InCHIANTI Study, a pro-
spective population-based study of Italian adults. Our study included 715 adults between 20 and 
74 years old. BPA concentrations were measured by liquid chromatography–mass spectrometry in 
24-hr urine samples. The main outcome measures were serum concentrations of total testosterone 
and 17β-estradiol.
results: Geometric mean urinary BPA concentration was 3.59 ng/mL [95% confidence interval (CI), 
3.42–3.77 ng/mL], and mean excretion was 5.63 μg/day (5th population percentile, 2.1 μg/day; 95th 
percentile, 16.4 μg/day). We found higher excretion rates among men, younger respondents, and those 
with increasing waist circumference (p = 0.013) and weight (p = 0.003). Higher daily BPA excretion was 
associated with higher total testosterone concentrations in men, in models adjusted for age and study 
site (p = 0.044), and in models additionally adjusted for smoking, measures of obesity, and urinary crea-
tinine concentrations (β = 0.046; 95% CI, 0.015–0.076; p = 0.004). We found no associations with the 
other serum measures. We also found no associations with the primary outcomes among women, but 
we did find an association between BPA and SHBG concentrations in the 60 premenopausal women.
conclusion: Higher BPA exposure may be associated with endocrine changes in men. The mecha-
nisms involved in the observed cross-sectional association with total testosterone concentrations 
need to be clarified.
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Meeker et al. (2010) studied serum thyroid 
and reproductive hormone levels in 167 men 
recruited through an infertility clinic and 
observed inverse relationships between urinary 
BPA concentrations and the free androgen 
index [ratio of testosterone to sex hormone–
binding globulin (SHBG)], estradiol, and 
thyroid-stimulating hormone. Given these 
findings, we hypothesized that higher urinary 
BPA concentrations would be associated with 
altered reproductive hormone concentrations 
in serum. Because a limitation of previous 
studies has been their reliance on single spot 
urine samples, we based our current analy-
sis on 24-hr urine collections, to provide a 
direct measure of daily excretion rates. We 
selected participants from the InCHIANTI 
study (Aging in the Chianti Area, Tuscany, 
Italy), a representive population-based study 
that was conducted in Chianti, Italy, from 
September 1998 to March 2000. Our analysis 
of the data from this sample provides the first 
report of daily BPA excretion levels in a large 
European cohort.
Materials and Methods
Study population. The InCHIANTI study 
(InCHIANTI 2010) was designed to identify 
risk factors for mid- and late-life morbidity 
and has been described extensively elsewhere 
(Ferrucci et al. 2000).
Briefly, InCHIANTI is a prospective 
 population-based study of a suburban and 
rural town population. City registries were 
used to randomly select adults who were liv-
ing in Greve in Chianti and in Bagno a Ripoli, 
Tuscany, Italy; a multistage sampling method 
was used (296 adults < 65 years old, 533 adults 
65–74 years old, and 102 adults ≥ 75 years old; 
response rate, 91.6% from baseline interview). 
In line with previous work, we have limited 
our analysis here to participants ≤ 74 years 
old. The Instituto Nazionale Riposo e Cura 
Anziani Institutional Review Board provided 
ethical approval for the study. Participants gave 
informed consent, or if they were unable to do 
so, a close relative provided surrogate consent.
Analysis of urinary BPA concentrations. 
Analysis of samples was performed (under 
contract) at the Brixham Environmental 
Laboratory, (Brixham, UK) in compliance 
with Good Laboratory Practice. Because orally 
administered BPA is considered to be rapidly 
and completely excreted, urine is the body fluid 
most appropriate for the biomonitoring assess-
ment of BPA exposure (see Calafat et al. 2005). 
To measure total (free and conjugated) urinary 
concentrations of BPA, we used the methods 
employed by NHANES (Calafat et al. 2008) 
and adopted by the Division of Environmental 
Health Laboratory Sciences, National Center 
for Environmental Health, Centers for Disease 
Control and Prevention to prepare the urine 
samples; we performed the analyses using 
online solid-phase extraction (SPE) coupled 
with high-performance liquid chromatography 
(LC)–isotope dilution tandem mass spectrom-
etry (MS/MS) with peak focusing. Analyses 
where carried out using a commercially 
available, integrated online SPE-LC system 
(Symbiosis Pharma System; Spark Holland 
BV, Emmen, the Netherlands) coupled with a 
triple-quadrupole mass spectrometer equipped 
with a heated electrospray ionization (HESI) 
interface (TSQ Quantum Ultra AM; Thermo 
Scientific, Hemel Hempstead, UK). Two 
major advantages of the Symbiosis Pharma 
system are that a new SPE cartridge is used 
for every analysis and that one SPE cartridge is 
prepared while one is being analyzed. This sys-
tem enabled a 7-min SPE-LC-HESI/MS/MS 
run time for each analysis point. A linear cal-
ibration was obtained from 0.50–100 μg/L 
(R2 > 0.996). The limit of detection (LOD) 
was < 0.50 μg/L BPA, the limit of quantita-
tion was 0.50 μg/L BPA, the lowest calibration 
standard with a signal height: noise height ratio 
> 10 (relative standard deviations < ±20%, all 
other standards < ±15%).
Outcomes. Participants who consented to 
donate a blood sample were asked also to col-
lect the urine for 24 hr in a vessel contain-
ing 3 g boric acid as preservative. During the 
3 days before blood and urine collection, the 
subjects consumed a diet free of meat and fish. 
On the morning of the day before the blood 
samples were drawn, participants urinated and 
flushed away the first voided urine and then 
began the urine collection. During the day 
and night, all the produced urine was saved 
into the plastic bottle stored at room tempera-
ture or in the refrigerator. After 24 hr, bottles 
were weighed and the total volume measured 
in the clinic.
First thing the next morning, after having 
been sedentary for 15 min, fasting blood sam-
ples were collected for routine blood exami-
nation. Aliquots of serum and plasma were 
subsequently prepared and stored at –80°C 
for additional analyses. A 24-hr urine sample 
aliquot (70 mL) was stored at –20°C until 
further analyses.
Testosterone that circulates in the blood 
binds predominantly to protein, with approxi-
mately 40% bound to the high-affinity SHBG 
and 60% to albumin with lower affinity. 
Measurement of serum testosterone typically 
includes estimating total testosterone (free 
plus bound), free testosterone (not protein 
bound), and bioavailable testosterone (not 
SHBG bound).
Total testosterone was assessed through a 
commercial radioimmunological assay (RIA) 
kit (Active Testosterone RIA DSL-4000; 
Diagnostic Systems Laboratories, Webster, 
TX, USA, distributed by Chematil, s.r.l., Angri 
SA, Angri, Italy). The minimum LOD was 
0.08 ng/mL. Intraassay coefficients of variation 
(CVs) for three different concentrations ranged 
from 7.8–9.6%, and interassay CVs ranged 
from 8.4–9.1%. Results were transformed and 
reported as nanograms per milliliter according 
to the manufacturer’s instructions.
SHBG level was measured by RIA (IRMA 
DSL-7400; Diagnostic Products Corp., Los 
Angeles, CA, USA). The analytical sensitivity 
was 3 nmol/L. The intraassay CVs for three 
different concentrations were 1.1–3.7%, and 
interassay CVs were 8.7–11.5%.
Free testosterone was estimated from 
measured total testosterone, SHBG, and albu-
min (4.3 g/dL) using the method described 
by Vermeulen et al. (1999; for a worked 
example, see the International Society for the 
Study of the Aging Male 2010).
Estradiol levels were measured using an 
ultrasensitive RIA (Ultra-sensitive Estradiol RIA 
DSL-4800; Diagnostic Systems Laboratories, 
distributed by Chematil). The theoretical sen-
sitivity was 2.2 pg/mL. Intraassay CVs across 
four different concentrations ranged from 
6.5–8.9%, and interassay CVs ranged from 
7.5–12.2% (at 108.7 pg/mL).
Statistical analyses. Descriptive statistics of 
urinary BPA concentration and serum hormone 
levels were tabulated. We calculated geometric 
means and distribution percentiles of two differ-
ent BPA measures. First, we measured the BPA 
volume concentration (expressed as micrograms 
of BPA/liter of urine). Then, we multiplied 
the BPA concentration by the urine collection 
rate (liters/day), which was measured consider-
ing the urine volume collected in 24 hr, and 
thus obtained the urinary excretion rate of BPA 
(expressed as micrograms/day).
We performed multivariate linear regres-
sion analyses to study the association between 
BPA and a broad range of demographic cova-
riates and possible confounders. Because the 
concentrations of daily BPA excretion were 
not normally distributed, we used natural log 
transformation when BPA was considered the 
dependant variable. BPA values were not trans-
formed when it was considered an explanatory 
variable in serum hormone examination. In all 
analyses, an upper age cutoff was 75 years to 
minimize the problem of comorbidity.
We adjusted our models by selecting dif-
ferent covariates. The variables included in our 
analyses were age, reported in years at the last 
birthday and used as a continuous variable; the 
two municipalities (study sites) where partici-
pants lived; waist circumference (centimeters) 
and weight (kilograms); and body mass index 
(BMI) was calculated as the weight (kilograms) 
divided by the square of height (meters). BMI 
was tested as a continuous variable and as a cat-
egorized dummy variable with subjects divided 
into underweight (< 18.5 kg/m2), recom-
mended weight (18.5–24.9 kg/m2), overweight 
(25.0–29.9 kg/m2), obese I (30.0–34.9 kg/m2), 
and obese II (≥ 35 kg/m2) categories. We also 
Bisphenol A daily excretion and sex hormones
Environmental Health Perspectives • volume 118 | number 11 | November 2010 1605
considered smoking status, which appeared to 
be correlated to BPA in unadjusted models.
Urinary creatinine concentration is com-
monly used to adjust within-day variation 
in metabolite analysis from single spot urine 
samples (Barr et al. 2005). Linear regression 
analysis using the outcome (hormone) meas-
ures as the dependant variable was performed 
first considering all the subjects and then con-
sidering men and women separately. Data 
analysis was performed using STATA (version 
10 SE; StataCorp LP, College Station, TX, 
USA); p < 0.05 was considered significant.
Results
The geometric mean urinary concentration of 
BPA was 3.59 ng/mL [95% confidence inter-
val (CI), 3.42–3.77 ng/mL; Table 1]. Based 
on the 24-hr urine collection, the daily excre-
tion rate of BPA had a geometric mean of 
5.63 μg/day but varied widely. The distribution 
was skewed, with a 10th percentile of 2.6 μg/day 
(95% CI, 2.5–2.8 μg/day) and a 90th per-
centile of 11.8 μg/day (95% CI, 10.9–12.7 
μg/day). Daily BPA excretion was lower among 
women than amomg men (p < 0.001 in models 
adjusted for age, sex, and study site) and lower 
with advancing age (p < 0.001). We obtained 
identical results both with and without cor-
rection for creatinine. In models adjusted for 
age, sex, and study site (Table 2), we found 
no associations between daily BPA excretion 
and years of education or smoking status. We 
did find associations with waist circumfer-
ence (β = 0.0062; 95% CI, 0.0016–0.0108; 
p = 0.013) and with weight (β = 0.0064; 95% 
CI, 0.0023–0.0104; p = 0.003).
In models for men, adjusted for age and 
study site, we found no association between 
BPA excretion and 17β-estradiol. However, we 
did find a significant association between daily 
BPA excretion and total testosterone concen-
tration (β = 0.0237; 95% CI, 0.0006–0.0468; 
p = 0.044). In models adjusted for age, study 
site, smoking, BMI, weight, waist, and urinary 
creatinine, the BPA association with total testos-
terone levels was highly significant (β = 0.046; 
95% CI, 0.015–0.076; p = 0.004; Table 3).
To explore further the association with 
testosterone in men, we examined associa-
tions with the derived measure of free tes-
tosterone, based on SHBG concentrations. 
The association between BPA excretion and 
free testosterone narrowly missed significance 
(p = 0.075 in fully adjusted models).
For women, the geometric mean of the 
17β-estradiol concentration was 6.89 pg/mL 
(Table 4), but this varied dramatically by meno-
pause status: 22.4 pg/mL (95% CI, 16.7–30.0 
pg/mL) in the 57 premenopausal women and 
5.3 pg/mL (95% CI, 4.8–5.7 pg/mL) in the 
290 postmenopausal women. In the models 
that tested hormone associations with BPA 
excretion among women (Table 4), we found 
no significant associations for either estradiol 
or total testosterone. Both SHBG concentra-
tion and the derived measure of free testoster-
one showed significant associations with BPA 
excretion in premenopausal women, although 
it should be noted that the method used 
(direct measure of free testosterone by RIA 
and calculation of the free androgen index) 
was not designed for measuring androgen 
Table 1. Geometric mean (GM) and selected population percentiles of urinary BPA concentrations and daily excretion of the study sample.
GM (95% CI)
Percentile (95% CI)
BPA variable n (%) 5th 10th 25th 50th 75th 90th 95th
All
UER (μg/day) 715 5.63 (5.37–5.90) 2.1 (1.9–2.3) 2.6 (2.5–2.8) 3.7 (3.6–3.9) 5.6 (5.1–5.8) 8.3 (7.7–8.7) 11.8 (10.9–12.7) 16.4 (14.0–20.1)
Urinary concentration (ng/mL) 720 3.59 (3.42–3.77) 1.3 (1.2–1.4) 1.6 (1.5–1.7) 2.3 (2.1–2.4) 3.5 (3.3–3.7) 5.4 (5.0–5.9) 8.0 (7.4–9.5) 11.5 (10.3–13.7)
Sex
Male
UER (μg/day) 332 (46.4) 6.26 (5.87–6.68) 2.5 (2.0–2.7) 3.0 (2.6–3.3) 4.3 (3.9–4.6) 6.1 (5.7–6.8) 9.0 (8.3–9.7) 12.5 (11.7–15.4) 16.7 (14.5–23.7)
Urinary concentration (ng/mL) 334 (46.4) 4.02 (3.76–4.31) 1.5 (1.4–1.6) 1.8 (1.6–2.0) 2.4 (2.3–2.7) 3.9 (3.6–4.3) 6.3 (5.7–6.7) 9.8 (8.1–10.9) 13.0 (10.7–14.8)
Female
UER (μg/day) 383 (53.6) 5.14 (4.81–5.49) 2.0 (1.8–2.2) 2.4 (2.2–2.6) 3.5 (3.2–3.7) 4.9 (4.5–5.3) 7.3 (6.7–8.2) 10.7 (9.9–12.3) 14.4 (12.2–20.4)
Urinary concentration (ng/mL) 386 (53.6) 3.25 (3.04–3.47) 1.1 (1.1–1.3) 1.4 (1.3–1.6) 2.1 (2.0–2.3) 3.2 (2.9–3.4) 4.7 (4.4–5.2) 7.2 (6.5–7.8) 11.0 (7.7–14.1)
Age group (years)
20–40
UER (μg/day) 109 (15.2) 6.61 (5.98–7.31) 2.6 (2.3–3.2) 3.2 (2.6–3.8) 4.7 (4.0–5.3) 6.7 (5.8–7.7) 8.9 (8.3–10.9) 12.5 (11.2–16.6) 16.9 (12.6–24.1)
Urinary concentration (ng/mL) 111 (15.4) 4.31 (3.86–4.82) 1.6 (1.2–2.1) 2.1 (1.6–2.3) 3.2 (2.4–3.6) 4.4 (4.0–4.8) 6.0 (5.6–6.8) 8.3 (7.0–12.0) 12.2 (8.4–17.4)
41–65
UER (μg/day) 157 (22.0) 6.69 (6.04–7.40) 2.7 (2.2–3.2) 3.2 (2.8–3.6) 4.6 (4.0–5.0) 6.2 (5.6–6.9) 9.2 (8.1–10.3) 16.1 (11.3–21.3) 23.8 (16.7–40.7)
Urinary concentration (ng/mL) 157 (21.8) 3.95 (3.53–4.42) 1.4 (1.2–1.5) 1.5 (1.4–2.0) 2.4 (2.1–2.8) 3.7 (3.3–4.4) 5.8 (5.1–6.7) 9.6 (7.5–15.3) 16.7 (11.1–22.3)
66–74
UER (μg/day) 449 (62.8) 5.10 (4.80–5.41) 1.9 (1.6–2.1) 2.4 (2.1–2.6) 3.5 (3.1–3.6) 4.9 (4.5–5.3) 7.4 (7.0–8.3) 10.9 (9.9–12.1) 14.2 (12.2–17.1)
Urinary concentration (ng/mL) 452 (62.8) 3.32 (3.12–3.53) 1.2 (1.1–1.3) 1.5 (1.3–1.6) 2.1 (2.0–2.3) 3.2 (2.9–3.4) 4.8 (4.4–5.6) 7.6 (7.0–8.9) 10.7 (9.3–12.8)
Table 2. Geometric means (GMs) of BPA excretion, by covariate status, plus age, sex, and study site 
using adjusted regression estimates of association.
Variable n (%) GM (μg/day) (95% CI) p-Valuea
Education (years)
0 3 (0.4) 4.72 (1.80 to 12.35) (dropped)
1–5 364 (50.9) 5.06 (4.75 to 5.39) —b
6–8 152 (21.3) 6.27 (5.59 to 7.02) 0.071
9–13 123 (17.2) 6.07 (5.46 to 6.75) 0.968
14–19 63 (8.8) 6.99 (5.99 to 8.17) 0.170
≥ 20 10 (1.4) 5.84 (3.82 to 8.94) 0.576
BMI category (kg/m2)
Underweight (BMI 0–18.5) 4 (0.6) 2.74 (1.29 to 5.81) (dropped)
Normal (BMI 18.5–25) 215 (30.1) 5.67 (5.22 to 6.16) —b
Overweight (BMI 25–30) 314 (43.9) 5.84 (5.43 to 6.27) 0.296
Obese I (BMI 30.1–34.9) 138 (19.3) 5.66 (5.04 to 6.34) 0.369
Obese II (BMI ≥ 35) 32 (4.5) 4.85 (3.94 to 5.98) 0.738
Unknown 12 (1.6) 3.46 (2.65 to 4.52) (dropped)
Smoking history
Never 380 (53.2) 3.20 (3.03 to 3.37) —b
Former 171 (23.9) 3.76 (3.50 to 4.05) 0.259
Current 164 (22.9) 3.95 (3.62 to 4.32) 0.773
Continuous measures
Waist circumference (cm) 715 β = 0.0062 (0.0016 to 0.0108) 0.013
Weight (kg) 715 β = 0.0064 (0.0023 to 0.0104) 0.003
Urinary creatinine concentration (mg/dL) 715 β = –0.0012 (–0.0025 to 0.0003) 0.116
aAdjusted for age, sex, and site. bThe base category against which the others are tested.
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concentrations in women, where the concen-
trations involved are at the very lowest LODs 
(Miller et al. 2004; Vermeulen et al. 1999).
Sensitivity analysis. For a sensitivity analy-
sis of our main finding, we examined the rela-
tionship between daily BPA excretion and 
total testosterone levels in men, excluding 
outlier BPA values above 25 μg/day (n = 7 
removed, ranging from 25.29–41.12 μg/day) 
(see Figure 1 for unadjusted model). In fully 
adjusted models as above, BPA excretion per 
day remained associated with total testoster-
one concentrations in men (β = 0.0521; 95% 
CI, 0.0172–0.08703; p = 0.004).
Post hoc analyses for bioavailable testoster-
one showed patterns similar to those reported 
for free testosterone (data not shown). 
Associations with estradiol: testosterone ratios 
were nonsignificant.
Discussion
In this study, we have reported for the first 
time the daily excretion levels of BPA among 
European adults in a large-scale and high-
quality population-based sample. After adjust-
ing for potential confounders, we have shown 
that higher BPA daily excretion was associated 
with an increase in serum total testosterone 
concentration in men.
These results are important because they 
provide the first report, using data from a 
large-scale human population, of associations 
between elevated exposure to BPA and altera-
tions in circulating hormone levels. They also 
illustrate that the extent of exposure to BPA is 
similar in this European urban and rural popu-
lation to exposures seen in the general adult 
population of the United States (Calafat et al. 
2008). Previous studies of the relationship 
between human exposure to BPA and endo-
crine function are sparse and involve reported 
alterations in androgens (gonadotrophins or 
testosterone) in urine or serum in both men 
and women, although the numbers of par-
ticipants were small (Hanaoka et al. 2002; 
Takeuchi and Tsutsumi 2002; Takeuchi et al. 
2004). Hanaoka et al. (2002) studied 42 occu-
pationally exposed male production workers 
and age-matched controls and showed that 
urinary BPA concentrations were inversely 
associated with follicle-stimulating hormone 
(FSH) but not with free testosterone or leuti-
nizing hormone. In a later study of 167 men 
recruited through an infertility clinic (Thuillier 
et al. 2009), BPA concentrations in urine 
were positively associated with both FSH 
and FSH:inhibin ratio and inversely associ-
ated with estradiol:testosterone ratio. Because 
FSH and inhibin B are the two hormones 
considered most predictive of semen quality, 
Thuillier et al. (2009) concluded that BPA 
may have been associated with adverse effects 
on Sertoli cells or their FSH receptors that led 
to altered inhibin B production and reduced 
semen quality. In an animal study, rats 
exposed to BPA in utero did not show signifi-
cant changes in circulating testosterone levels 
in adulthood, which suggests normal function-
ing of Leydig and Sertoli cells (Goodman et al. 
2009). Because estrogens and androgens can 
exert differential effects in function depend-
ing on the cell type and its stage of develop-
ment, the consequences of BPA exposure on 
adult reproductive and somatic tissues merits 
further attention.
Our results showed an association with 
total testosterone concentrations but no sig-
nificant trend in 17β-estradiol levels with 
higher BPA excretion in men. The results 
reported by Meeker et al. (2010) are consis-
tent with those reported here, although the 
positive trend (p = 0.17) between BPA and 
testosterone reported by Meeker et al. (2010) 
did not reach statistical significance in their 
smaller study. Mendiola et al. (2010) reported 
finding no association between urinary BPA 
concentrations and testosterone levels in 
375 male partners of pregnant women; in 
addition to differences in study group, their 
urinary BPA concentrations appear substan-
tially lower than in our study sample.
Plausible explanations for our finding of an 
increase in total testosterone include a reduc-
tion in aromatase activity (Akingbemi et al. 
2004; Huang and Leung 2009; Nativelle-
Serpentini et al. 2003), which would lead to 
a decrease in the conversion of testosterone 
to estradiol. Because BPA has been shown 
to possess antiandrogenic activity (Bonefeld-
Jørgensen et al. 2007; Lee et al. 2003), an 
alternative explanation could be that a block-
ade of androgen-binding sites alters feedback 
control mechanisms that leads to an increase 
in circulating testosterone. Lee et al. (2003) 
showed BPA to affect multiple steps in the 
activation and function of the androgen recep-
tor, including noncompetitive inhibition of 
binding of endogenous androgens, nuclear 
localization, and transactivation, with uncer-
tain consequences for androgen homeostasis. 
In our study, associations with the derived 
measure of free testosterone narrowly missed 
statistical significance.
Alternatively, there could be differential 
effects of BPA on the metabolism of testos-
terone and estrogen. A study of steroid hor-
mone production in rat ovarian cells showed 
that BPA increased both testosterone synthesis 
and the mRNA expression of steroidogenic 
enzymes (Zhou et al. 2008). BPA also sig-
nificantly decreased the activity of enzymes 
involved in the hydroxylation of testosterone, 
including the cytochrome P450 isoforms for 
testosterone 2 α-hydroxylase and testosterone 
6 β-hydroxylase, CYP2C11/6 and CYP3A2/1, 
respectively, in isolated rat livers (Hanioka 
Table 3. Simple and fully adjusted regression models of the associations between BPA (μg/day) and 17β-estradiol and testosterone concentrations for men.
Geometric mean (95% CI)
Age and study-site adjusted Fully adjusteda
Hormone n β-Coefficient (95% CI) p-Value β-Coefficient (95% CI) p-Value
17β-Estradiol (pg/mL) 293 12.89 (12.26 to 13.56) –0.00004 (–0.0086 to 0.0085) 0.992 0.0002 (–0.011 to 0.011) 0.975
Total testosterone (ng/mL) 307 4.55 (4.42 to 4.69) 0.0237 (0.0006 to 0.0468) 0.044 0.046 (0.015 to 0.076) 0.004
SHBG (nmol/mL) 316 80.84 (76.60 to 85.30) –0.0009 (–0.0095 to 0.0076) 0.830 0.0011 (–0.0075 to 0.0096) 0.805
Free testosterone (ng/dL) 316 4.72 (4.50 to 4.95) 0.0081 (–0.0012 to 0.0175) 0.089 0.0088 (–0.0009 to 0.0185) 0.075
aFull models were adjusted for age, study site, smoking, BMI, weight, waist, and urinary creatinine concentration.
Table 4. Simple and fully adjusted regression models of the associations between BPA (μg/day) and 17β-estradiol, testosterone, and SHBG concentrations for women.
Age and study-site adjusted Fully adjusteda
Hormone n Geometric mean (95% CI) β-Coefficient (95% CI) p-Value β-Coefficient (95% CI) p-Value
Premenopause
17β-Estradiol (pg/mL) 57 22.4 (16.7–30.0) –0.026 (–0.066 to 0.014) 0.204 –0.022 (–0.066 to 0.0229) 0.325
Total testosterone (ng/mL) 61 0.69 (0.61–0.77) –0.004 (–0.015 to 0.007) 0.451 –0.007 (–0.018 to 0.004) 0.192
SHBG (nmol/mL) 60 134.3 (111.6–161.5) 0.029 (0.004 to 0.054) 0.024 0.038 (0.013 to 0.063) 0.004
Postmenopause
17β-Estradiol (pg/mL) 290 5.3 (4.8–5.7) –0.002 (–0.010 to 0.005) 0.516 –0.003 (–0.010 to 0.005) 0.448
Total testosterone (ng/mL) 294 0.54 (0.49–0.59) –0.0003 (–0.0036 to 0.0030) 0.871 –0.001 (–0.004 to 0.002) 0.555
SHBG (nmol/mL) 299 105.2 (98.8–112.1) 0.002 (–0.004 to 0.008) 0.541 0.003 (–0.003 to 0.009) 0.272
aFull models adjusted for age, study site, smoking, BMI, weight, waist, and urinary creatinine concentration.
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et al. 1998), both of which could lead to a net 
increase in circulating testosterone. The pos-
sibility that BPA could interfere with the RIA 
used to quantify serum testosterone is unlikely 
given the low cross-reactivity shown by the 
anti-testosterone antibody used in the assay 
and is further discounted by mathematical 
modeling studies showing negligible effects of 
xenoestrogens on the displacement of bound 
hormone and tracer during binding and 
extraction steps in vitro (Heringa et al. 2004).
It is also plausible that an androgenic envi-
ronment leads to alterations in the metabolism 
of BPA, that is, reverse causation. Metabolism 
of BPA in the intestine and liver catalyzed by 
uridine diphosphate-glucuronosyl transferase 
(UGT) yields the major urinary metabolite 
BPA-glucuronide (Teeguarden et al. 2005). 
The level of both UGT activity and transcrip-
tion has been shown to be downregulated by 
androgens (Guillemette et al. 1997; Takeuchi 
et al. 2004), which could result in an increase 
in serum BPA concentration under hyper-
androgenic conditions. However, it is unlikely 
that such metabolic change could alter 24-hr 
urinary BPA excretion in the context of 
repeated ingestion of BPA at the population 
level and the limited increase in testosterone 
concentrations evident in our analysis.
Urinary BPA concentrations have previ-
ously been reported in 100 pregnant European 
women, with 82% of the study population 
showing detectable levels of BPA, median 
concentration 1.2 ng/mL (Ye et al. 2008). 
This concentration is lower than the mean 
value presented here, 3.59 ng/mL (95% CI, 
3.42–3.77 ng/mL), although there are dif-
ferences in age and sex profiles. Most studies 
have reported values from spot urine samples 
with or without correction for creatinine, 
with mean concentrations around 3 ng/mL 
(Dekant and Volkel 2008; Vandenberg et al. 
2010) and 95th percentiles in the range of 11.5 
ng/mL (Ye et al. 2008) to 16 ng/mL (Calafat 
et al. 2005). Here, we used 24-hr urine col-
lection to calculate a mean daily excretion rate 
of 5.63 μg/day (95% CI, 5.67–5.90 μg/day). 
In an earlier Japanese study, Arakawa et al. 
(2004) reported median daily urinary excre-
tions of BPA of 1.3–5.0 μg/day, with a maxi-
mum daily intake of BPA per body weight 
of 0.23 μg/kg/day based on 24-hr urine sam-
ples collected from 36 men; the median daily 
uptake was given as 0.02 μg/kg body weight. 
In controlled, acute human exposure studies, 
peak urinary concentrations of BPA metabo-
lites were 4,500–6,800 μg/L 6 hr after oral 
administration of 60–80 μg/kg body weight. 
Based on these figures and assuming com-
plete and rapid excretion, Dekant and Volkel 
(2008) suggested that a daily excretion rate of 
around 5 μg/L, as seen in the general popula-
tion, indicates ingestion of < 25 μg of BPA in 
the hours prior to sampling (the maximum 
daily reference dose is 50 μg/kg/day). However, 
there are no actual in vivo data on the rate at 
which unconjugated BPA is converted to BPA-
glucuronide in humans, only estimates. BPA 
is lipophilic with a log octanol–water partition 
coefficient (log Kow) between 2.2 and 3.82, and 
it may partition to lipid-rich tissues, a sugges-
tion supported by population-based half-lives 
for BPA calculated by Stahlhut et al. (2009) 
to be significantly longer than previous predic-
tions of 6 hr. Given the correlations with BMI 
and waist circumference seen here, a true esti-
mation of exposure rates remains a priority.
There are limitations to this study that 
should be borne in mind when interpreting 
the results. First, replication is required in 
an independent study population to exclude 
chance as an explanation, although the small 
p-value in fully adjusted models and the broad 
consistency with previous work suggest this is 
unlikely. Second, the analysis is based on a 
single day of BPA excretion, which is clearly 
not a perfect measure of longer term exposure 
given that human health effects are most likely 
associated with long-term low-dose exposure. 
However, using the 24-hr urine specimens 
is likely to be more accurate than previously 
published work, which has been based on spot 
urine samples with post hoc adjustment to try 
to correct for concentration effects. Spot urine 
samples themselves have been shown to be 
moderately sensitivity for predicting an indi-
vidual’s tertile categorization (Mahalingaiah 
et al. 2008). Misclassification due to this 
single-day snapshot of excretion will have 
resulted in a smaller (diluted) estimate of the 
strength of association between BPA and total 
testosterone concentrations: the true associa-
tions are likely to be much stronger.
Third, the cross-sectional nature of the 
association reported here needs to be treated 
with caution. It is also theoretically possible, 
for example, that those with higher testoster-
one concentrations alter their diet in such a 
way as to increase BPA exposure, or, as noted 
above, that higher testosterone concentra-
tions are themselves responsible for altering 
metabolism of BPA. It is unclear, however, 
why altered metabolism would alter our 
measure of 24-hr excretion systematically, 
because all BPA is thought to be excreted in 
the urine in humans sooner or later. We pre-
viously reported positive associations between 
urinary BPA and prevalence of cardio vascular 
disease (Lang et al. 2008; Melzer et al. 2010). 
The relationship between circulating testos-
terone and cardiovascular risk remains to be 
comprehensively established, although an 
increased risk of cardiovascular adverse events 
was recently reportedly in a trial of testoster-
one supplementation in older men (Basaria 
et al. 2010).
Future work needs to replicate the asso-
ciation found and to clarify the mechanisms 
involved. Showing that raised BPA levels pre-
cede the increase in testosterone concentra-
tions would establish the temporal sequence 
of changes and exclude reverse causation. 
However, a concurrent change in testoster-
one levels with BPA exposure would remain 
biologically important. A large-scale exposure 
trial may be necessary to clarify the association 
we identified, although the logistics and ethics 
of such a trial would require careful thought.
Conclusions
Mean daily exposure to BPA among an Italian 
adult population sample is in line with previous 
estimates from the United States, with wide 
variations around the mean. We found an asso-
ciation between higher daily excretion of BPA 
and total testosterone concentrations among 
men. The mechanisms involved in this possible 
endocrine disruption need clarification.
RefeRences
Akingbemi BT, Sottas CM, Koulova AI, Klinefelter GR, 
Hardy MP. 2004. Inhibition of testicular steroidogenesis by 
the xenoestrogen bisphenol A is associated with reduced 
pituitary luteinizing hormone secretion and decreased 
steroidogenic enzyme gene expression in rat Leydig cells. 
Endocrinology 145:592–603.
Arakawa C, Fujimaki K, Yoshinaga J, Imai H, Serizawa S, 
Shiraishi H. 2004. Daily urinary excretion of bisphenol A. 
Environ Health Prev Med 9:22–26.
Barr DB, Wilder LC, Caudill SP, Gonzalez AJ, Needham LL, 
Pirkle JL. 2005. Urinary creatinine concentrations in the 
U.S. population: implications for urinary biologic monitor-
ing measurements. Environ Health Perspect 113:192–200.
Basaria S, Coviello A, Travison T, Storer T, Farwell W, Jette A, 
et al. 2010. Adverse events associated with testosterone 
administration. N Engl J Med 363:109–122
Beronius A, Rudén C, Håkansson H, Hanberg A. 2010. Risk to 
all or none? A comparative analysis of controversies in 
the health risk assessment of bisphenol A. Reprod Toxicol 
29:132–146.
Bonefeld-Jørgensen EC, Long M, Hofmeister MV, Vinggaard AM. 
2007. Endocrine-disrupting potential of bisphenol A, bisphe-
nol A dimethacrylate, 4-n-nonylphenol, and 4-n-octylphenol 
in vitro: new data and a brief review. Environ Health 
Perspect 115:69–76.
Burridge E. 2003. Bisphenol A: product profile. Eur Chem News 
17:14–20.
Calafat AM, Kuklenyik Z, Reidy JA, Caudill SP, Ekong J, 
Needham LL. 2005. Urinary concentrations of bisphenol 
A and 4-nonylphenol in a human reference population. 
Environ Health Perspect 113:391–395.
Calafat AM, Ye X, Wong LY, Reidy JA, Needham LL. 2008. 
Figure 1. Scatter plot of BPA excretion per day 
against total testosterone concentrations, with 
unadjusted linear regression line (BPA outlier 
 values censored at < 25 μg/day).
10
8
6
4
2
0
To
ta
l t
es
to
st
er
on
e 
(n
g/
m
L)
0 10 20 2515
BPA excretion (µg/day)
5
Galloway et al.
1608 volume 118 | number 11 | November 2010 • Environmental Health Perspectives
Exposure of the U.S. population to bisphenol A and 
4- tertiary-octylphenol: 2003–2004. Environ Health Perspect 
116:39–44.
Dekant W, Völkel W. 2008. Human exposure to bisphenol A by 
biomonitoring: methods, results and assessment of envi-
ronmental exposures. Toxicol Appl Pharmacol 228:114–134.
Ferrucci L, Bandinelli S, Benvenuti E, Di Iorio A, Macchi C, 
Harris TB, et al. 2000. Subsystems contributing to the 
decline in ability to walk: bridging the gap between epi-
demiology and geriatric practice in the InCHIANTI study. 
J Am Geriatr Soc 48:1618–1625.
Goodman JE, Witorsch RJ, McConnell EE, Sipes IG, Slayton TM, 
Yu CJ, et al. 2009. Weight-of-evidence evaluation of repro-
ductive and developmental effects of low doses of bisphe-
nol A. Crit Rev Toxicol 20:1–75.
Guillemette C, Levesque E, Beaulieu M, Turgeon D, Hum DW, 
Belanger A. 1997. Differential regulation of two uridine 
diphospho-glucuronosyltransferases, UGT2B15 and 
UGT2B17, in human prostate LNCaP cells. Endocrinology 
138:2998–3005.
Hanioka N, Jinno H, Nishimura T, Ando M. 1998. Suppression of 
male-specific cytochrome P450 isoforms by bisphenol A in 
rat liver. Arch Toxicol 72:387–394.
Hanaoka T, Kawamura N, Hara K, Tsugane S. 2002. Urinary 
bisphenol A and plasma hormone concentrations in male 
workers exposed to bisphenol A diglycidyl ether and mixed 
organic solvents. Occup Environ Med 59:625–628.
Heringa M, van der Burg B, van Eijkeren J Hermens J. 2004. 
Xenoestrogenicity in in vitro assays is not caused by dis-
placement of endogenous estradiol from serum proteins.
Toxicol Sci 82:154–163.
Huang H, Leung LK. 2009. Bisphenol A downregulates CYP19 
transcription in JEG-3 cells. Toxicol Lett 189:248–252.
InCHIANTI (Invecchiare in CHIANTI). 2010. The Study Design. 
Available: http://www.inchiantistudy.net/study.html 
[accessed 29 September 2010].
International Society for the Study of the Aging Male. 2010. 
Free and Bioavailable Testosterone Calculator. Available: 
http://www.issam.ch/freetesto.htm [accessed 12 August 
2010].
Kruger T, Long M, Bonefeld-Jørgensen EC. 2008. Plastic com-
ponents affect the activation of the aryl hydrocarbon and 
the androgen receptor. Toxicology 246:112–123.
Lang IA, Galloway TS, Scarlett A, Henley WE, Depledge M, 
Wallace RB, et al. 2008. Association of urinary bisphenol 
A concentration with medical disorders and laboratory 
abnormalities in adults. JAMA 300:1303–1310.
Lee HJ, Chattopadhyay S, Gong EY, Ahn RS, Lee K. 2003. 
Antiandrogenic effects of bisphenol A and nonylphenol on 
the function of the androgen receptor. Toxicol Sci 75:40–46.
Mahalingaiah S, Meeker JD, Pearson KR, Calafat AM, Ye X, 
Petrozza J, et al. 2008. Temporal variability and predictors 
of urinary bisphenol A concentrations in men and women. 
Environ Health Perspect 116:173–178.
Meeker JD, Calafat AM, Hauser R. 2010. Urinary bisphenol A 
concentrations in relation to serum thyroid and repro-
ductive hormone levels in men from an infertility clinic. 
Environ Sci Technol 44:1458–1463.
Melzer D, Lang IA, Galloway TS. 2009. Association of bisphenol 
A with diabetes and other abnormalities, reply [Letter]. 
JAMA 301:721–722.
Melzer D, Lang IA, Scarlett A, Galloway T. 2008. Bisphenol A, 
age, ethnicity and health outcomes [Abstract]. Epidemiology 
19:S379.
Melzer D, Rice NE, Lewis C, Henley WE, Galloway TS. 2010. 
Association of urinary bisphenol A concentration with 
heart disease: evidence from NHANES 2003/06. PLoS 
One 5:e8673; doi:10.1371/journal.pone.0008673 [Online 
13 January 2010].
Mendiola J, Jørgensen N, Andersson AM Calafat A, Ye X, 
Redmon JB, et al. 2010. Are environmental levels of bis-
phenol A associated with reproductive function in fertile 
men? Environ Health Perspect 118:1286–1291.
Miller KK, Rosner W, Lee H, Hier J, Sesmilo G, Schoenfeld D, 
et al. 2004. Measurement of free testosterone in normal 
women and women with androgen deficiency: comparison 
of methods. J Clin Endocrinol Metab 89:525–533.
Moriyama K, Tagami T, Akamizu T, Usui T, Saijo M, 
Kanamoto N, et al. 2002. Thyroid hormone action is dis-
rupted by bisphenol A as an antagonist. J Clin Endocrinol 
Metab 87:5185–5190.
Nativelle-Serpentini C, Richard S, Seralini GE, Sourdaine 
P. 2003. Aromatase activity modulation by lindane and 
 bisphenol-A in human placental JEG-3 and transfected 
kidney E293 cells. Toxicol In Vitro 17:413–422.
Newbold RR, Padilla-Banks E, Jefferson WN, Heindel JJ. 2008. 
Effects of endocrine disruptors on obesity. Int J Androl 
31:201–208.
Okada H, Tokunaga T, Liu XH, Takayanagi S, Matsushima A, 
Shimohigashi Y. 2008. Direct evidence revealing structural 
elements essential for the high binding ability of bisphenol 
A to human estrogen-related receptor-gamma. Environ 
Health Perspect 116:32–38.
Richter CA, Birnbaum LS, Farabollini F, Newbold RR, Rubin BS, 
Talsness CE, et al. 2007. In vivo effects of bisphenol A in 
laboratory rodent studies. Reprod Toxicol 24:199–224.
Ropero AB, Alonso-Magdalena P, Garcia-Garcia E, Ripoll C, 
Fuentes E, Nadal A. 2008. Bisphenol A disruption of the 
endocrine pancreas and blood glucose homeostasis. Int J 
Androl 31:194–200.
Stahlhut RW, Welshons WV, Swan SH. 2009. Bisphenol A 
data in NHANES suggest longer than expected half life, 
substantial nonfood exposure, or both. Environ Health 
Perspect 117:784–789.
Takeuchi T, Tsutsumi O. 2002. Serum bisphenol A concentra-
tions showed gender differences, possibly linked to andro-
gen levels. Biochem Biophys Res Commun 291:76–78.
Takeuchi T, Tsutsumi O, Ikezuki Y, Takai Y, Taketani Y. 2004. 
Positive relationship between androgen and the endo-
crine disruptor bisphenol A in normal women and women 
with ovarian dysfunction. Endocr J 51:165–169.
Talsness CE, Andrade AJM, Kuriyama SN, Taylor JA, 
vom Saal FS. 2009. Components of plastic: experimental 
studies in animals and relevance for human health. Philos 
Trans R Soc B Biol Sci 364:2079–2096.
Teeguarden JG, Waechter JM, Clewell HJ, Covington TR, 
Barton HA. 2005. Evaluation of oral and intravenous route 
pharmacokinetics, plasma protein binding and uterine tis-
sue dose metrics of bisphenol A, a physiologically based 
pharmacokinetic approach. Toxicol Sci 85:823–838.
Thuillier R, Manku G, Wang Y, Culty M. 2009. Changes in MAPK 
pathway in neonatal and adult testis following fetal estro-
gen exposure and effects on rat testicular cells. Microsc 
Res Tech 72:773–786.
Vandenberg LN, Chahoud I, Heindel JJ, Padmanabhan V, 
Paumgartten JR, Schoenfelder G. 2010. Urinary, circu-
lating, and tissue biomonitoring studies indicate wide-
spread exposure to bisphenol A. Environ Health Perspect 
118:1055–1070.
Vandenberg LN, Hauser R, Marcus M, Olea N, Welshons WV. 
2007. Human exposure to bisphenol A (BPA). Reprod 
Toxicol 24:139–177.
Vermeulen A, Verdonck L, Kaufman JM. 1999. A critical evalua-
tion of simple methods for the estimation of free testoster-
one in serum. J Clin Endocrinol Metab 84:3666–3672.
vom Saal FS, Akingbemi BT, Belcher SM, Birnbaum LS, Crain 
DA, et al. 2007. Chapel Hill bisphenol A expert panel con-
sensus statement: integration of mechanisms, effects in 
animals and potential to impact human health at current 
levels of exposure. Reprod Toxicol 24:131–138.
Ye X, Pierik FH, Hauser R, Duty S, Angerer J, Park MM, et al. 
2008. Urinary metabolite concentrations of organophos-
phorous pesticides, bisphenol A, and phthalates among 
pregnant women in Rotterdam, the Netherlands: the 
Generation R study. Environ Res 108:260–267.
Zhou W, Liu J, Liao L, Han S, Liu J. 2008. Effect of bisphenol A on 
steroid hormone production in rat ovarian theca- interstitial 
and granulosa cells. Mol Cell Endocrinol 283:12–18.
